Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

1.3K
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
1.3K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165
Antibody Actions01:26

Antibody Actions

3.9K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.9K
Antibody Structure01:10

Antibody Structure

52.5K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
52.5K
Hybridoma Technology01:31

Hybridoma Technology

13.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.2K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of Novel 2-Morpholine Tetrahydroisoquinoline CXCR4 Antagonists with Unique Properties.

Journal of medicinal chemistry·2026
Same author

Discovery of Non-prostanoid EP4 Agonists for the Treatment of Inflammatory Bowel Disease.

Journal of medicinal chemistry·2026
Same author

Total Body Irradiation in Australia and New Zealand: A 2024 Practice Survey on Changing Patterns of Care.

Journal of medical imaging and radiation oncology·2026
Same author

Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplant.

Annals of hematology·2026
Same author

Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C.

Nature communications·2026
Same author

An Ultra-High Throughput Cell-Based Mass Spectrometry Flux Assay as a Pathway-Selective In Situ Screening Approach.

Analytical chemistry·2025

Related Experiment Video

Updated: May 5, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

6.4K

Antibody-drug conjugates: current status and future directions.

Heidi L Perez1, Pina M Cardarelli2, Shrikant Deshpande2

  • 1Bristol-Myers Squibb Research & Development, Princeton, NJ 08543, USA.

Drug Discovery Today
|November 19, 2013
PubMed
Summary

Antibody-drug conjugates (ADCs) utilize monoclonal antibodies (mAbs) to target cancer cells with potent drugs. Optimized ADCs show improved efficacy and tolerability, driving significant clinical interest.

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.1K

Related Experiment Videos

Last Updated: May 5, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

6.4K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.1K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Antibody-drug conjugates (ADCs) are designed to leverage monoclonal antibody (mAb) specificity for targeted delivery of cytotoxic drugs to tumor cells.
  • The development of ADCs involves careful consideration of antigen target selection and conjugation methods.
  • Optimization of antibody, linker, and drug components is crucial for effective targeted therapy.

Purpose of the Study:

  • To highlight the design principles and components of Antibody-Drug Conjugates (ADCs).
  • To discuss the advancements in ADC technology leading to improved efficacy and tolerability.
  • To underscore the growing clinical interest in ADCs based on recent successes.

Main Methods:

  • Review of ADC design parameters, including antigen selection and conjugation strategies.
  • Analysis of antibody, linker, and drug component optimization.
  • Evaluation of advancements in ADC technology and clinical outcomes.

Main Results:

  • Modern ADCs incorporate non-immunogenic mAbs, linkers with balanced stability, and highly potent cytotoxic agents.
  • Optimized ADC design contributes to improved therapeutic efficacy and patient tolerability.
  • Recent clinical successes demonstrate the potential of next-generation ADCs.

Conclusions:

  • ADCs represent a promising targeted therapy approach in oncology.
  • Continued advancements in ADC design and components are leading to enhanced clinical performance.
  • The therapeutic class of ADCs is experiencing a resurgence of interest due to positive clinical outcomes.